Respiratory COPD Exacerbation vs Mechanical Ventilation Expert

"Respiratory COPD Exacerbation - BAP-65 and DECAF Score" is a mobile app designed to help with health practitioner in assessing the severity and predicting the outcome in acute exacerbation of chronic obstructive pulmonary disease (COPD) by using BAP-65 and DECAF Score. Chronic obstructive pulmonary disease (COPD) is defined as a common preventable and treatable disease, characterised by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients. There are several features of "Respiratory COPD Exacerbation - BAP-65 and DECAF Score", namely: - Simple and very easy to use COPD app. - Precise calculation and classification with BAP-65 score. - Easy calculation and interpretation of DECAF score. - Assess severity and predict outcome of acute COPD exacerbation. - It is totally free. Download now! Both BAP-65 and DECAF score in "Respiratory COPD Exacerbation - BAP-65 and DECAF Score" app correlates well with both in-hospital mortality and need for mechanical ventilation in patients with COPD. The BAP-65 system is a score composed of 4 variables. All of them are available upon presentation to the hospital. The B letter stands for Blood Urea Nitrogen (BUN) and it is positive if level is above 25 mg/dL. The A letter stands for Altered Mental Status and it is counted positive when the initial Glasgow Coma Scale (GCS) is 14 or less, or when the physician has designated that the patient was disoriented, stuporous or in coma. The P letter stands for Pulse and it is positive when the initial pulse is above 109 beats/min. Finally, an additional point will be added if the patient was above 65 years old. While DECAF score is a simple, reliable, accurate prediction tool could potentially improve patient care, by identifying patients suitable for hospital discharge or for more intensive therapy / monitoring. DECAF is simple to calculate and apply at the bedside. It requires an assessment of the patient’s usual level of breathlessness and function: the eMRCD score. Disclaimer: all calculations must be re-checked and should not be used alone to guide patient care, nor should they substitute for clinical judgment. Calculations in this "Respiratory COPD Exacerbation - BAP-65 and DECAF Score" app might be different with your local practice. Consult to expert doctor whenever necessary.

Caution! This app is intended for intensive care physicians. If you are NOT a physician and would like to use it anyway, please consult your physician before using this app or making any medical decisions. This app has endorsement for usage in the Russian Federation. Many doctors deal with the treatment of patients with varying degrees of acute respiratory failure (ARF). But the choice of the optimal method and, especially, the timely correction of the parameters of invasive and non-invasive mechanical lung ventilation often cause difficulties, especially for young doctors. Unfortunately, expensive ventilation machines, without their skillful use, are not a guarantee of an improvement in the mortality rate in ARF. This has been especially evident during the COVID-19 pandemic. In international clinical practice, it is customary to determine the degree of ARF by the oxygenation index (the ratio of the partial pressure of oxygen in arterial blood (PaO2) to the fraction of inspired oxygen (FiO2)). This indicator is also included in most "severity of illness" scoring systems (SOFA, APACHE II-III, etc.). However PaO2 estimation is only possible after collecting the arterial blood for laboratory monitoring of blood gases, making it costly and invasive. In 2020-2021 a multicenter research was carried out at five clinical hospitals in Volgograd, Russia, which included 1038 patients with acute lung injury and acute respiratory distress syndrome against the background of viral (COVID-19) and bacterial pneumonia. The goals of the research were firstly, to develop a non-invasive method for determining the oxygenation index (PaO2 / FiO2) based on oxygen saturation (SpO2), and secondly, to define general criteria for correcting the parameters of invasive and non-invasive mechanical ventilation. This application is based on the results of the research. The relationship between SpO2 and PaO2 index values was determined for various FiO2 and types of respiratory support. The app also implements the general principle of oxygen therapy - from less to more invasive. The app allows the user not only to choose the most effective method of respiratory support, but also timely learn about the need for its correction. Every clinician knows that the mortality rate in patients with ARF is greatly influenced by the validity of the beginning and end of Invasive Mechanical Ventilation treatment - and this app solves this problem. The educational effect of this app should also be noted. It will help doctors to quickly master and more competently use expensive ventilation machines, which, of course, will have a beneficial effect on the results of treatment of patients with ARF. The following sources were used to create the app: 1. Brown SM, Grissom CK, Moss M, Rice TW, Schoenfeld D, Hou PC, Thompson BT, Brower RG; NIH/NHLBI PETAL Network Collaborators. Nonlinear Imputation of Pao2/Fio2 From Spo2/Fio2 Among Patients With Acute Respiratory Distress Syndrome. Chest. 2016 Aug;150(2):307-13. doi: 10.1016/j.chest.2016.01.003. Epub 2016 Jan 19. PMID: 26836924; PMCID: PMC4980543. 2. Bilan N, Dastranji A, Ghalehgolab Behbahani A. Comparison of the spo2/fio2 ratio and the pao2/fio2 ratio in patients with acute lung injury or acute respiratory distress syndrome. J Cardiovasc Thorac Res. 2015;7(1):28-31. doi: 10.15171/jcvtr.2014.06. Epub 2015 Mar 29. PMID: 25859313; PMCID: PMC4378672. 3. Yoshida T, Takegawa R, Ogura H. [Ventilatory strategy for ARDS]. Nihon Rinsho. 2016 Feb;74(2):279-84. Japanese. PMID: 26915253. 4. Fan E, Brodie D, Slutsky AS. Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment. JAMA. 2018 Feb 20;319(7):698-710. doi: 10.1001/jama.2017.21907. PMID: 29466596. 5. Петров, В. И. Эволюция клинико-фармакологических и терапевтических принципов лечения инфекции COVID-19 / Петров В. И. [и др. ]. - Москва : ГЭОТАР-Медиа, 2021. - 312 с. - DOI: 10.33029/9704-6386-4-ECPC-2021-1-312. - ISBN 978-5-9704-6386-4.